Nandrolone phenpropionate

CAS No. 62-90-8

Nandrolone phenpropionate( —— )

Catalog No. M22550 CAS No. 62-90-8

Nandrolone phenpropionate is an androgen receptor agonist. It mainly used to treat women with breast cancer and osteoporosis.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 48 In Stock
10MG 35 In Stock
25MG 53 In Stock
50MG 73 In Stock
100MG 107 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Nandrolone phenpropionate
  • Note
    Research use only, not for human use.
  • Brief Description
    Nandrolone phenpropionate is an androgen receptor agonist. It mainly used to treat women with breast cancer and osteoporosis.
  • Description
    Nandrolone phenpropionate is an androgen receptor agonist. It mainly used to treat women with breast cancer and osteoporosis.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Endocrinology/Hormones
  • Target
    Androgen Receptor (AR)
  • Recptor
    androgen receptor
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    62-90-8
  • Formula Weight
    406.6
  • Molecular Formula
    C27H34O3
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    CC12CCC3C(C1CCC2OC(=O)CCC4=CC=CC=C4)CCC5=CC(=O)CCC35
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Kahn S B , Conroy J F , Brodsky I . Effect of nandrolone phenpropionate on myelopoiesis[J]. Journal of Medicine, 1974, 5(6):303.
molnova catalog
related products
  • DL-α-Tocopherol

    Antioxidant.

  • JNJ-63576253

    JNJ-63576253 is a potent and orally active full antagonist of androgen receptor (AR), with IC50s of 37 and 54 nM for F877L mutant AR and wild-type AR in LNCaP cells.?

  • 2-hydroxy Flutamide

    2-hydroxy Flutamide is competitive inhibition of androgen receptor (AR)?for the treatment of prostate cancer.